Breast Cancer Coverage from Every Angle

Nadia Harbeck, MD, on Trastuzumab Emtansine and Pertuzumab vs. Trastuzumab, Pertuzumab, and Taxane After Anthracyclines in Early Breast Cancer

Posted: Wednesday, June 24, 2020

Nadia Harbeck, MD, of the University of Munich, discusses data from the phase III KAITLIN trial showing that replacing adjuvant taxane and trastuzumab with trastuzumab emtansine did not significantly improve efficacy or overall safety for patients with high-risk HER2-positive early breast cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.